Compare BGS & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGS | VOR |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | 86 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.5M | 562.6M |
| IPO Year | 2004 | 2021 |
| Metric | BGS | VOR |
|---|---|---|
| Price | $5.92 | $15.19 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 4 | 10 |
| Target Price | $4.38 | ★ $64.78 |
| AVG Volume (30 Days) | ★ 2.3M | 696.6K |
| Earning Date | 06-03-2026 | 01-01-0001 |
| Dividend Yield | ★ 15.05% | N/A |
| EPS Growth | ★ 83.02 | 2.86 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,828,687,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.67 | $0.13 |
| 52 Week High | $8.06 | $49.95 |
| Indicator | BGS | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 72.78 | 54.78 |
| Support Level | $3.98 | $11.76 |
| Resistance Level | N/A | $16.95 |
| Average True Range (ATR) | 0.25 | 1.13 |
| MACD | 0.02 | 0.16 |
| Stochastic Oscillator | 67.25 | 55.23 |
B&G Foods Inc is an American packaged-food manufacturer. It operate in a single industry segment and manufacture, sell and distribute a diverse portfolio of high-quality shelf-stable and frozen foods across the United States, Canada and Puerto Rico. Its products include frozen and canned vegetables, vegetable, canola and other cooking oils, vegetable shortening, cooking sprays, oatmeal and other hot cereals, fruit spreads, canned meats and beans, bagel chips, spices, seasonings, hot sauces, wine vinegar, The company's main brands are Ac'cent, B&G, B&M, Baker's Joy, Bear Creek Country Kitchens, Cary's, Cream of Rice, Cream of Wheat, Devonsheer, Don Pepino, Durkee, Emeril's, Grandma's Molasses, MacDonald's.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.